Clinical trials for Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)

53 currently recruiting clinical trials
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04256317
Phase 3 monothérapie
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS Chronic myelomonocytic leukemia (CMML) Other MDS
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High Very high
Required IPSS-M prognostic scores
High Very high
Required molecular CPSS scores
Intermediate-2 High
Excluded previous treatments
Chemotherapy
3 recruiting sites
Taiho Oncology
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06465953 #2023-510155-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required IPSS-M prognostic scores
Low Moderately low Moderately high High Very high
Excluded previous treatments
Chemotherapy Allogeneic stem cell transplant
6 recruiting sites
Servier
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06641414 #2024-517247-31-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High Very high
Required IPSS-M prognostic scores
High Very high
Excluded previous treatments
Allogeneic stem cell transplant
1 recruiting site
Ascentage Pharma Group Inc.
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06456346 #2023-505232-36-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Essential thrombocythemia
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Cytoreductive therapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06499285 #2024-516009-22-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
EPO / Growth factors
Required medullary blasts
< 5 %
Required transfusion dependency statuses
Transfusion-dependent
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded previous treatments
Systemic Treatment-Naive Chemotherapy Allogeneic stem cell transplant Erythroid maturation agent
4 recruiting sites
Takeda
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05198960
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera Essential thrombocythemia Primary myelofibrosis
Required genetic anomalies
JAK2
19 recruiting sites
Hôpital Universitaire de Brest
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06479135
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
14 recruiting sites
Kartos Therapeutics
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06093672 #2022-502276-23-00
Phase de traitement principale
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Polycythemia vera
Required genetic anomalies
JAK2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Targeted therapy Cytoreductive therapy
9 recruiting sites
Italfarmaco
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06847867 #2024-519928-24-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
EPO / Growth factors Erythroid maturation agent
Required transfusion dependency statuses
Transfusion-dependent
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded genetic anomalies
del(5q)
5 recruiting sites
GlaxoSmithKline
Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) Multiple myeloma #NCT04935684
Required histologic types
B cell lymphoma T cell lymphoma Hodgkin lymphoma CLL (Chronic Lymphocytic Leukemia) Symptomatic multiple myeloma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CHU de Clermont-Ferrand